Clair Health

About Clair Health

Clair Health is a San Francisco-based health tech company developing a noninvasive, continuous hormone monitoring system for women. The company was founded in 2025 by Stanford University graduates Jenny Duan and Abhinav Agarwal. Duan, who studied symbolic systems with a focus on AI ethics, was motivated by her personal frustration with inadequate cycle tracking apps and her experience working with women whose health concerns were dismissed due to a lack of quantitative data. Agarwal has a background in wearable hardware, algorithms, and previously contributed to the development of a noninvasive continuous glucose monitor.

The company's core product is a wrist-worn wearable designed to provide real-time insights into a woman's hormonal health. It utilizes a proprietary stack of 10 biosensors, including biomagnetic sensors, to measure physiological signals like skin temperature, heart rate variability, and electrodermal activity. AI models then process this data on the user's device to infer and track key hormone levels—including estrogen, progesterone, Luteinizing Hormone (LH), and Follicle-Stimulating Hormone (FSH)—without the need for blood or urine tests. This approach aims to shift women's healthcare from reactive to preventative by providing continuous data for managing fertility, hormonal conditions like PCOS, athletic performance, and perimenopause.

Clair Health operates on a direct-to-consumer business model. The company plans to launch the product in November 2026 as a wellness device, with intentions to seek FDA clearance in the future. The reported pricing structure involves a one-time fee of $369 for the device and a $9.99 monthly subscription for the accompanying app. In June 2026, the company announced it had raised $11.6 million in a seed funding round led by Khosla Ventures, with participation from firms like a16z speedrun and investors such as Anne Wojcicki, co-founder of 23andMe. The company reported a waitlist of over 25,000 people ahead of its launch.